REGN Annual Cash & Cash Equivalents
$2.73 B
-$375.90 M-12.10%
31 December 2023
Summary:
As of January 22, 2025, REGN annual cash & cash equivalents is $2.73 billion, with the most recent change of -$375.90 million (-12.10%) on December 31, 2023. During the last 3 years, it has risen by +$536.30 million (+24.45%). REGN annual cash & cash equivalents is now -12.10% below its all-time high of $3.11 billion, reached on December 31, 2022.REGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Quarterly Cash And Cash Equivalents
$2.01 B
+$91.10 M+4.74%
30 September 2024
Summary:
As of January 22, 2025, REGN quarterly cash and cash equivalents is $2.01 billion, with the most recent change of +$91.10 million (+4.74%) on September 30, 2024. Over the past year, it has dropped by -$718.20 million (-26.31%). REGN quarterly cash and cash equivalents is now -48.63% below its all-time high of $3.92 billion, reached on March 31, 2023.REGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.1% | -26.3% |
| 3 y3 years | +24.4% | -26.3% |
| 5 y5 years | +86.0% | -26.3% |
REGN Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -12.1% | at low | -48.6% | +4.7% |
| 5 y | 5-year | -12.1% | +68.8% | -48.6% | +39.9% |
| alltime | all time | -12.1% | >+9999.0% | -48.6% | >+9999.0% |
Regeneron Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.01 B(+4.7%) |
| June 2024 | - | $1.92 B(-26.2%) |
| Mar 2024 | - | $2.60 B(-4.7%) |
| Dec 2023 | $2.73 B(-12.1%) | $2.73 B(+26.8%) |
| Sept 2023 | - | $2.15 B(+11.1%) |
| June 2023 | - | $1.94 B(-50.5%) |
| Mar 2023 | - | $3.92 B(+26.1%) |
| Dec 2022 | $3.11 B(+7.6%) | $3.11 B(-11.0%) |
| Sept 2022 | - | $3.49 B(+2.8%) |
| June 2022 | - | $3.40 B(+1.5%) |
| Mar 2022 | - | $3.35 B(+15.9%) |
| Dec 2021 | $2.89 B(+31.5%) | $2.89 B(-15.9%) |
| Sept 2021 | - | $3.43 B(+65.6%) |
| June 2021 | - | $2.07 B(+44.1%) |
| Mar 2021 | - | $1.44 B(-34.5%) |
| Dec 2020 | $2.19 B(+35.6%) | $2.19 B(+39.5%) |
| Sept 2020 | - | $1.57 B(-21.0%) |
| June 2020 | - | $1.99 B(-9.8%) |
| Mar 2020 | - | $2.21 B(+36.5%) |
| Dec 2019 | $1.62 B(+10.2%) | $1.62 B(+16.8%) |
| Sept 2019 | - | $1.38 B(+32.5%) |
| June 2019 | - | $1.05 B(-38.8%) |
| Mar 2019 | - | $1.71 B(+16.4%) |
| Dec 2018 | $1.47 B(+80.6%) | $1.47 B(+34.9%) |
| Sept 2018 | - | $1.09 B(+18.5%) |
| June 2018 | - | $917.88 M(-10.0%) |
| Mar 2018 | - | $1.02 B(+25.4%) |
| Dec 2017 | $812.70 M(+51.8%) | $812.70 M(+2.6%) |
| Sept 2017 | - | $792.07 M(+6.4%) |
| June 2017 | - | $744.31 M(-8.3%) |
| Mar 2017 | - | $811.77 M(+51.7%) |
| Dec 2016 | $535.20 M(-33.9%) | $535.20 M(-41.8%) |
| Sept 2016 | - | $920.36 M(+42.4%) |
| June 2016 | - | $646.51 M(+7.0%) |
| Mar 2016 | - | $604.21 M(-25.3%) |
| Dec 2015 | $809.10 M(+24.7%) | $809.10 M(+23.6%) |
| Sept 2015 | - | $654.59 M(+67.6%) |
| June 2015 | - | $390.55 M(-23.1%) |
| Mar 2015 | - | $507.91 M(-21.7%) |
| Dec 2014 | $648.72 M(+21.1%) | $648.72 M(+0.3%) |
| Sept 2014 | - | $646.55 M(+7.7%) |
| June 2014 | - | $600.13 M(+29.9%) |
| Mar 2014 | - | $461.86 M(-13.8%) |
| Dec 2013 | $535.61 M(+132.6%) | $535.61 M(+103.5%) |
| Sept 2013 | - | $263.21 M(-31.0%) |
| June 2013 | - | $381.68 M(+111.6%) |
| Mar 2013 | - | $180.36 M(-21.7%) |
| Dec 2012 | $230.28 M(-52.4%) | $230.28 M(+93.5%) |
| Sept 2012 | - | $119.00 M(-30.8%) |
| June 2012 | - | $171.94 M(-56.4%) |
| Mar 2012 | - | $394.58 M(-18.4%) |
| Dec 2011 | $483.61 M(+329.6%) | $483.61 M(+134.3%) |
| Sept 2011 | - | $206.40 M(-18.8%) |
| June 2011 | - | $254.31 M(+87.9%) |
| Mar 2011 | - | $135.38 M(+20.3%) |
| Dec 2010 | $112.57 M(-45.6%) | $112.57 M(-65.4%) |
| Sept 2010 | - | $325.29 M(+190.4%) |
| June 2010 | - | $112.00 M(-4.5%) |
| Mar 2010 | - | $117.31 M(-43.3%) |
| Dec 2009 | $207.07 M(-16.4%) | $207.07 M(-17.3%) |
| Sept 2009 | - | $250.32 M(-7.8%) |
| June 2009 | - | $271.47 M(+36.3%) |
| Mar 2009 | - | $199.10 M(-19.7%) |
| Dec 2008 | $247.80 M(-50.3%) | $247.80 M(-21.3%) |
| Sept 2008 | - | $314.68 M(+7.7%) |
| June 2008 | - | $292.13 M(-43.9%) |
| Mar 2008 | - | $520.88 M(+4.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $498.93 M(+109.7%) | $498.93 M(+412.2%) |
| Sept 2007 | - | $97.42 M(-11.2%) |
| June 2007 | - | $109.64 M(-29.9%) |
| Mar 2007 | - | $156.48 M(-34.2%) |
| Dec 2006 | $237.88 M(+28.9%) | $237.88 M(+41.9%) |
| Sept 2006 | - | $167.66 M(+45.8%) |
| June 2006 | - | $114.96 M(-37.0%) |
| Mar 2006 | - | $182.33 M(-1.2%) |
| Dec 2005 | $184.51 M(+93.8%) | $184.51 M(+4.8%) |
| Sept 2005 | - | $176.09 M(+21.3%) |
| June 2005 | - | $145.20 M(-1.8%) |
| Mar 2005 | - | $147.82 M(+55.2%) |
| Dec 2004 | $95.23 M(-19.5%) | $95.23 M(-9.3%) |
| Sept 2004 | - | $105.05 M(-14.5%) |
| June 2004 | - | $122.83 M(-29.4%) |
| Mar 2004 | - | $174.03 M(+47.1%) |
| Dec 2003 | $118.28 M(+47.7%) | $118.28 M(-60.4%) |
| Sept 2003 | - | $298.62 M(+130.3%) |
| June 2003 | - | $129.66 M(-32.3%) |
| Mar 2003 | - | $191.59 M(+139.3%) |
| Dec 2002 | $80.08 M(-67.6%) | $80.08 M(+6.0%) |
| Sept 2002 | - | $75.57 M(+8.9%) |
| June 2002 | - | $69.37 M(-48.8%) |
| Mar 2002 | - | $135.47 M(-45.2%) |
| Dec 2001 | $247.39 M(+698.6%) | $247.39 M(+147.5%) |
| Sept 2001 | - | $99.97 M(-30.1%) |
| June 2001 | - | $142.96 M(-22.1%) |
| Mar 2001 | - | $183.62 M(+492.7%) |
| Dec 2000 | $30.98 M(+30.7%) | $30.98 M(-37.6%) |
| Sept 2000 | - | $49.64 M(-39.3%) |
| June 2000 | - | $81.75 M(+565.0%) |
| Mar 2000 | - | $12.29 M(-48.1%) |
| Dec 1999 | $23.70 M(+19.7%) | $23.70 M(+0.9%) |
| Sept 1999 | - | $23.50 M(+14.1%) |
| June 1999 | - | $20.60 M(-5.5%) |
| Mar 1999 | - | $21.80 M(+10.1%) |
| Dec 1998 | $19.80 M(-31.5%) | $19.80 M(-12.4%) |
| Sept 1998 | - | $22.60 M(+0.4%) |
| June 1998 | - | $22.50 M(+16.6%) |
| Mar 1998 | - | $19.30 M(-33.2%) |
| Dec 1997 | $28.90 M(-16.2%) | $28.90 M(-28.3%) |
| Sept 1997 | - | $40.30 M(-21.6%) |
| June 1997 | - | $51.40 M(+84.2%) |
| Mar 1997 | - | $27.90 M(-19.1%) |
| Dec 1996 | $34.50 M(+5.5%) | $34.50 M(-8.0%) |
| Sept 1996 | - | $37.50 M(-23.3%) |
| June 1996 | - | $48.90 M(+310.9%) |
| Mar 1996 | - | $11.90 M(-63.6%) |
| Dec 1995 | $32.70 M(+38.6%) | $32.70 M(+454.2%) |
| Sept 1995 | - | $5.90 M(-64.9%) |
| June 1995 | - | $16.80 M(+32.3%) |
| Mar 1995 | - | $12.70 M(-46.2%) |
| Dec 1994 | $23.60 M(+88.8%) | $23.60 M(+54.2%) |
| Sept 1994 | - | $15.30 M(-15.0%) |
| June 1994 | - | $18.00 M(+125.0%) |
| Mar 1994 | - | $8.00 M(-36.0%) |
| Dec 1993 | $12.50 M(-23.8%) | $12.50 M(-68.5%) |
| Sept 1993 | - | $39.70 M(+402.5%) |
| June 1993 | - | $7.90 M(-21.8%) |
| Mar 1993 | - | $10.10 M(-38.4%) |
| Dec 1992 | $16.40 M(-37.4%) | $16.40 M(-14.6%) |
| Sept 1992 | - | $19.20 M(-12.7%) |
| June 1992 | - | $22.00 M(-11.6%) |
| Mar 1992 | - | $24.90 M(-5.0%) |
| Dec 1991 | $26.20 M(+20.2%) | $26.20 M(-25.1%) |
| Sept 1991 | - | $35.00 M(-10.7%) |
| June 1991 | - | $39.20 M(+79.8%) |
| Dec 1990 | $21.80 M | $21.80 M |
FAQ
- What is Regeneron Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Regeneron Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Regeneron Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of REGN is $2.73 B
What is the all time high annual cash & cash equivalents for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual cash & cash equivalents is $3.11 B
What is Regeneron Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, REGN annual cash & cash equivalents has changed by -$375.90 M (-12.10%)
What is Regeneron Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of REGN is $2.01 B
What is the all time high quarterly cash and cash equivalents for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly cash and cash equivalents is $3.92 B
What is Regeneron Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, REGN quarterly cash and cash equivalents has changed by -$718.20 M (-26.31%)